Abstract:AbstractBackgroundInflammatory cytokine interleukin‐6 (IL‐6) plays a pivotal role in skeletal muscle degradation after intra‐abdominal sepsis (IAS), with mechanism remained to be elucidated. Indoleamine 2,3‐dioxygenase 1 (IDO‐1), a key enzyme in converting tryptophan into kynurenine, could be activated by IL‐6, and kynurenine has been shown to be involved in muscle degradation. We hypothesized that IL‐6 could promote muscle degradation via tryptophan–IDO‐1–kynurenine pathway in IAS patients.MethodsSerum and rectus abdominis (RA) were obtained from IAS or non‐IAS patients. Mouse model of IAS‐induced muscle wasting was generated by caecal ligation and puncture (CLP) and lipopolysaccharide (LPS) injection. IL‐6 signalling was blocked by anti‐mouse IL‐6 antibody (IL‐6‐AB), and the IDO‐1 pathway was blocked by navoximod. To elucidate the role of kynurenine in muscle mass and physiology, kynurenine was administered to IAS mice treated with IL‐6‐AB.ResultsCompared to non‐IAS patients, kynurenine levels in serum (+2.30‐fold vs. non‐IAS, P < 0.001) and RA (+3.11‐fold vs. non‐IAS, P < 0.001) were elevated, whereas tryptophan levels in serum (−53.65% vs. non‐IAS, P < 0.01) and RA (−61.39% vs. non‐IAS, P < 0.01) were decreased. Serum IL‐6 level of the IAS group was significantly higher compared to non‐IAS patients (+5.82‐fold vs. non‐IAS, P = 0.01), and muscle cross‐sectional area (MCSA) was markedly reduced compared to non‐IAS patients (−27.73% vs. non‐IAS, P < 0.01). In animal experiments, IDO‐1 expression was up‐regulated in the small intestine, colon and blood for CLP or LPS‐treated mice, and there was correlation (R2 = 0.66, P < 0.01) between serum and muscle kynurenine concentrations. Navoximod significantly mitigated IAS‐induced skeletal muscle loss according to MCSA analysis (+22.94% vs. CLP, P < 0.05; +23.71% vs. LPS, P < 0.01) and increased the phosphorylated AKT (+2.15‐fold vs. CLP, P < 0.01; +3.44‐fold vs. LPS, P < 0.01) and myosin heavy chain (+3.64‐fold vs. CLP, P < 0.01; +2.13‐fold vs. LPS, P < 0.01) protein expression in myocytes. In the presence of anti‐IL‐6 antibody, a significantly decreased IDO‐1 expression was observed in the small intestine, colon and blood in CLP or LPS mice (all P < 0.01), whereas the decrease of MCSA was alleviated (+37.43% vs. CLP + IgG, P < 0.001; +30.72% vs. LPS + IgG, P < 0.001). In contrast, additional supplementation of kynurenine decreased the MCSA in septic mice treated with IL‐6‐AB (both P < 0.01).ConclusionsThis study provided novel insights into the tryptophan–IDO‐1–kynurenine‐dependent mechanisms that underlie inflammatory cytokine‐induced skeletal muscle catabolism during intra‐abdominal sepsis.

Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats

[Role of Interleukin-2 in the Functional Myocardial Impairment Induced by Anoxia and Reoxygenation].

Interleukin 6 Increases Dysfunction of Organs in Sepsis Rats Through Sirtuin 1

[Effects of Interleukin-2 on Ventricular Papillary Muscle of Rat and the Possible Mechanism].

[Interleukin-2 Reduces Calcium Handling Capacity of Rat Ventricular Myocytes During Anoxia/reoxygenation].

IL-6 Deficiency Attenuates Skeletal Muscle Atrophy by Inhibiting Mitochondrial ROS Production through the Upregulation of PGC-1α in Septic Mice

Transcriptome Analysis of Immune Receptor Activation and Energy Metabolism Reduction as the Underlying Mechanisms in Interleukin-6-Induced Skeletal Muscle Atrophy

Myeloid cell-derived interleukin-6 induces vascular dysfunction and vascular and systemic inflammation

Elevation of IL-6 and IL-33 Levels in Serum Associated with Lung Fibrosis and Skeletal Muscle Wasting in a Bleomycin-Induced Lung Injury Mouse Model

Interleukin-6 in Patients With Heart Failure and Preserved Ejection Fraction

Interleukin 11 therapy causes acute left ventricular dysfunction

Fibroblast-derived interleukin-6 exacerbates adverse cardiac remodeling after myocardial infarction

The clinical significance of interleukin‐6 in heart failure: results from the BIOSTAT‐CHF study

Interleukin-6 receptor inhibition modulates the immune reaction and restores titin phosphorylation in experimental myocarditis

Correlation Between the Expression of Interleukin-6 Messenger-Rna in Myocardium of End-Stage Cardiac Failure and Cardiac Functional Parameters in Patients with Ischemic and Dilated Cardiomyopathy

Role of interleukin-6 in regulation of immune responses to remodeling after myocardial infarction

IL-6 knockout ameliorates myocardial remodeling after myocardial infarction by regulating activation of M2 macrophages and fibroblast cells

Interleukin-6 mediates pulmonary vascular permeability in a two-hit model of ventilator-associated lung injury

Myocardial toxic effects during recombinant interleukin-2 therapy

Interleukin‐6 Promotes Skeletal Muscle Catabolism by Activating Tryptophan–indoleamine 2,3‐dioxygenase 1–kynurenine Pathway During Intra‐abdominal Sepsis

Interleukin-6 trans-signaling regulates monocyte chemoattractant protein-1 production in immune-mediated necrotizing myopathy